Friday, 20 February 2026 BB Biotech FY 2025 results release — FY 2025 analyst conference call: 20 February 2026 at 10.00am CET – [join Webscast]
Friday, 20 February 2026 BB Biotech FY 2025 results release — FY 2025 analyst conference call: 20 February 2026 at 10.00am CET – [join Webscast]
Discover how we identify and capitalize on biotech innovation.
Read the storyBreakthrough innovation, structural growth and global demand are reshaping healthcare and creating long-term value opportunities for investors.
ViewWe aim to turn scientific innovation into sustainable value through disciplined investing and deep biotech expertise.
ViewA multidisciplinary team combining scientific knowledge and investment experience to make high-conviction decisions.
ViewBB BIOTECH AG | BION
Closing prices as of 11 Feb 2026
An overview of market dynamics, capital flows, and innovation trends shaping long-term biotech returns.
Read the storySee portfolio structure, key exposures, and concentration at a glance.
ViewExplore current holdings, focus areas, and the science driving each investment.
ViewA disciplined process combining research depth, risk control, and long-term perspective.
ViewOur most recent financial report, including performance, portfolio developments, and key highlights.
Available on 20.02.2026Detailed financial statements, notes, and disclosures providing full transparency on results and financial position.
ViewMonthly snapshots of key figures, portfolio composition, and performance metrics.
ViewAccess to historical reports, factsheets, and financial documents from previous periods.
ViewArticles, videos, and conversations exploring biotech, markets, and our investment thinking.
ViewOfficial company announcements and regulatory communications.
ViewPrice-sensitive disclosures published in line with regulatory requirements.
ViewDirect contact details for media and press enquiries.
ViewDiscover how we identify and capitalize on biotech innovation.
Read the storyBreakthrough innovation, structural growth and global demand are reshaping healthcare and creating long-term value opportunities for investors.
ViewWe aim to turn scientific innovation into sustainable value through disciplined investing and deep biotech expertise.
ViewA multidisciplinary team combining scientific knowledge and investment experience to make high-conviction decisions.
View
BB BIOTECH AG | BION
Closing prices as of 11 Feb 2026
An overview of market dynamics, capital flows, and innovation trends shaping long-term biotech returns.
Read the storySee portfolio structure, key exposures, and concentration at a glance.
ViewExplore current holdings, focus areas, and the science driving each investment.
ViewA disciplined process combining research depth, risk control, and long-term perspective.
ViewOur most recent financial report, including performance, portfolio developments, and key highlights.
Available on 20.02.2026Detailed financial statements, notes, and disclosures providing full transparency on results and financial position.
ViewMonthly snapshots of key figures, portfolio composition, and performance metrics.
ViewAccess to historical reports, factsheets, and financial documents from previous periods.
ViewArticles, videos, and conversations exploring biotech, markets, and our investment thinking.
ViewOfficial company announcements and regulatory communications.
ViewPrice-sensitive disclosures published in line with regulatory requirements.
ViewDirect contact details for media and press enquiries.
ViewUpdate your browser to view this website correctly.
BB Biotech currently does not have an active share buyback program and is not conducting any share repurchases at this time.
